Last Price
21.00
Today's Change
-0.09 (0.42%)
Day's Change
20.45 - 21.11
Trading Volume
151,491
Overview
Market Cap
2 Billion
Shares Outstanding
127 Million
Avg Volume
461,663
Avg Price (50 Days)
20.16
Avg Price (200 Days)
17.52
PE Ratio
17.50
EPS
1.20
Earnings Announcement
29-Jul-2024
Previous Close
21.09
Open
21.10
Day's Range
20.45 - 21.11
Year Range
10.02 - 25.95
Trading Volume
151,570
Price Change Highlight
1 Day Change
-0.43%
5 Day Change
10.06%
1 Month Change
10.99%
3 Month Change
1.25%
6 Month Change
43.05%
Ytd Change
-15.39%
1 Year Change
46.65%
3 Year Change
1586.75%
5 Year Change
1775.00%
10 Year Change
1400.00%
Max Change
194.12%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Apps
Top Articles
1
CEO Morning Brief
Australia Business Conditions Soften in April as Employment Growth Slows
2
CEO Morning Brief
ANZ Faces Regulator Probe on Australian Government Bond Sale
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
